Lombard Odier Asset Management Switzerland SA Raises Holdings in Johnson & Johnson $JNJ

Lombard Odier Asset Management Switzerland SA grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 132,124 shares of the company’s stock after acquiring an additional 11,708 shares during the quarter. Johnson & Johnson comprises 1.0% of Lombard Odier Asset Management Switzerland SA’s portfolio, making the stock its 15th biggest position. Lombard Odier Asset Management Switzerland SA’s holdings in Johnson & Johnson were worth $20,182,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Daiwa Securities Group Inc. lifted its position in Johnson & Johnson by 9.3% during the second quarter. Daiwa Securities Group Inc. now owns 502,314 shares of the company’s stock valued at $76,729,000 after buying an additional 42,797 shares in the last quarter. Sentinus LLC lifted its holdings in shares of Johnson & Johnson by 7.3% during the 2nd quarter. Sentinus LLC now owns 5,939 shares of the company’s stock valued at $907,000 after acquiring an additional 406 shares in the last quarter. SVB Wealth LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth $5,075,000. L2 Asset Management LLC increased its holdings in Johnson & Johnson by 40.7% in the 2nd quarter. L2 Asset Management LLC now owns 3,068 shares of the company’s stock valued at $469,000 after purchasing an additional 887 shares in the last quarter. Finally, First Wilshire Securities Management Inc. raised its position in Johnson & Johnson by 9.4% in the second quarter. First Wilshire Securities Management Inc. now owns 2,403 shares of the company’s stock valued at $367,000 after purchasing an additional 206 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Raymond James Financial upped their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday, October 20th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $203.15.

Johnson & Johnson Stock Down 0.2%

JNJ stock opened at $201.51 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a 50 day simple moving average of $194.45 and a 200-day simple moving average of $175.90. The company has a market capitalization of $485.50 billion, a P/E ratio of 19.45, a PEG ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $207.81.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.